www.bioscience.co.uk
Sales & Support: +44 (0)1223 316 855

*

C5/C5a, Human, mAb 561

Catalogue number:
HM2076-20UG
Supplier:
Size:
20 µg _$$_
Product is available in:
  • UK
  • Ireland
  • Europe
  • USA
  • Rest of World
£132.00 Shipping is calculated in checkout
Applications:

Functional studies, Immuno assays

Immunogen:

Human C5/C5a

Product Description:

Monoclonal antibody 561 recognizes the N-terminus of C5. The antibody reacts both with intact C5 (190 kDa) as with C5a (115 kDa).The complement system is composed of over 30 proteins, activated in response to tissue injury, invading pathogens or other foreign surfaces. The complement pathways can be divided in the activation pathways and lytic pathway. The activation pathways lead via C3 to the cleavage of the fifth complement component C5 into C5a and C5b, resulting in activation of the lytic pahwayC5a was first described as a cleavage product of C5 with chemotactic and anaphylatoxic properties. Further characterization revealed that C5a is an essential part of the innate immune response and evidence now suggests that it may also play a role in adaptive immunity. Complement fragment C5a is a 74 residue pro-inflammatory polypeptide. C5a induces smooth muscle contraction, increases vascular permeability, causes degranulation of mast cells and basophils, and release of lysosomal enzymes. In addition C5a stimulates the directed migration of neutrophils, eosinophils, basophils and monocytes. C5a binds to at least two seven-transmembrane domain receptors, C5aR (C5R1, CD88) and C5L2 (gpr77), expressed ubiquitously on a wide variety of cells but particularly on the surface of immune cells like macrophages, neutrophils and T cells. The former is a well-established receptor that initiates G-protein-coupled signaling via mitogen-activated protein kinase pathways, thereby by inducing synthesis of cytokines such as TNF-alpha, IL-1beta,- IL-6 and IL-8. Its in vivo blockade greatly reduces inflammatory injury. Much less is known about C5L2, occupancy of which by C5a does not initiate increased intracellular Ca(2+).The widespread expression of C5a receptors throughout the body allows C5a to elicit a broad range of effects. Thus, C5a has been found to be a significant pathogenic driver in a number of immuno-inflammatory diseases. Nowadays C5a is also implicated in non-immunological functions associated with developmental biology, CNS development and neurodegeneration, tissue regeneration, and haematopoiesis.

HM2076-20UG C5/C5a, Human, mAb 561
HM2076-20UG C5/C5a, Human, mAb 561
Details Cat number & supplier Size Price
C3/C3a, Human, mAb 2898 HM2075-20UG · Hycult Biotech
HM2075-20UG
Hycult Biotech
20 µg £132.00
20 µg
view
C5/C5a, Human, mAb 557 HM2077-20UG · Hycult Biotech
HM2077-20UG
Hycult Biotech
20 µg £132.00
20 µg
view
C3a/C3a des Arg, Human, mAb 2991 HM2074-20UG · Hycult Biotech
HM2074-20UG
Hycult Biotech
20 µg £132.00
20 µg
view
C5a/C5a des Arg, Human, mAb 2942 HM2078-20UG · Hycult Biotech
HM2078-20UG
Hycult Biotech
20 µg £132.00
20 µg
view
C3/C3a, Human, mAb 474 HM2073-20UG · Hycult Biotech
HM2073-20UG
Hycult Biotech
20 µg £132.00
20 µg
view
C5a/C5a des Arg, Human, mAb 2952 HM2079-20UG · Hycult Biotech
HM2079-20UG
Hycult Biotech
20 µg £132.00
20 µg
view
C3/C3b, Human, mAb 755 HM2072-20UG · Hycult Biotech
HM2072-20UG
Hycult Biotech
20 µg £132.00
20 µg
view
C5/C5b, Human, mAb 568 HM2080-20UG · Hycult Biotech
HM2080-20UG
Hycult Biotech
20 µg £132.00
20 µg
view
LL-37/CAP-18, Human, mAb 1-1C12 HM2071-20UG · Hycult Biotech
HM2071-20UG
Hycult Biotech
20 µg £132.00
20 µg
view
LL-37/CAP-18, Human, mAb 3D11 HM2070-20UG · Hycult Biotech
HM2070-20UG
Hycult Biotech
20 µg £132.00
20 µg
view